{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:22:07Z","timestamp":1792671727959,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.urolonc.2025.10.012","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T09:56:58Z","timestamp":1762595818000},"page":"124.e9-124.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["PSA response to predict progression in metastatic hormone-sensitive prostate cancer (mHSPC) patients. When is the optimal time point?"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4102-0820","authenticated-orcid":false,"given":"Roc\u00edo","family":"Mart\u00ednez-Corral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"P\u00e9rez-Fentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Bardella-Altarriba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Vera-Ballesteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnau","family":"Abella-Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Ant\u00f3n Fuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Elena","family":"Mart\u00ednez-Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Picola-Brau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"L\u00f3pez-Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"G\u00f3mez-Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Beamud-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Francisco","family":"Su\u00e1rez-Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Angel","family":"L\u00f3pez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Garc\u00eda-Puche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"\u00c1lvarez-Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"De Pablos-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.10.012_bib0001","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0002","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0003","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0004","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","article-title":"Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)","volume":"24","author":"Hussain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0005","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.eururo.2024.03.036","volume":"86","author":"Saad","year":"2024","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.urolonc.2025.10.012_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2025.05.006","article-title":"PSA kinetics and predictors of PSA response in metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors","volume":"43","author":"Mart\u00ednez-Corral","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0007","first-page":"58","article-title":"Prostate-specific antigen at 3 months as a predictor of radiologic progression-free survival in metastatic hormone-sensitive Prostate cancer treated with apalutamide: analysis of 633 patients in a real-world database","volume":"70","author":"Hassi Roman","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0008","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/JU.0000000000004158","article-title":"Early prostate-specific antigen response by 6 months is predictive of treatment effect in metastatic hormone sensitive prostate cancer: an exploratory analysis of the TITAN trial","volume":"212","author":"Roy","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0009","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0010","first-page":"123","article-title":"Three- and seven-month prostate-specific antigen levels as prognostic markers for overall survival in metastatic hormone-sensitive prostate cancer: results from SWOG S1216, a phase 3 randomized trial of androgen deprivation plus orteronel or bicalutamide","volume":"7","author":"Parikh","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0011","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/cncr.24064","article-title":"Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy","volume":"115","author":"Choueiri","year":"2009","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.urolonc.2025.10.012_bib0012","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2490-14-33","article-title":"Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer","volume":"29","author":"Tomioka","year":"2014","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0013","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.3390\/jcm13206221","article-title":"Ultralow prostate-specific antigen (PSA) levels and improved oncological outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with apalutamide: a real-world multicentre study","volume":"13","author":"L\u00f3pez-Abad","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0014","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0015","first-page":"192","article-title":"Prostate-specific antigen nadir and cancer-control outcomes in real-world apalutamide-treated metastatic hormone-sensitive Prostate cancer patients: a single-center analysis","volume":"7","author":"Wenzel","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0016","first-page":"1","article-title":"Prostate-specific antigen kinetics in Asian patients with metastatic castration-sensitive prostate cancer treated with apalutamide in the TITAN trial: a post hoc analysis","volume":"31","author":"Ye","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0017","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41391-023-00696-w","article-title":"Survival outcomes of real-world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors","volume":"27","author":"Gebrael","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0018","first-page":"1","article-title":"Clinical significance of PSA dynamics in castration-sensitive prostate cancer treated with ARSI doublet therapy: a multicenter study","volume":"86","author":"Urabe","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0019","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0020","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"PEACE-1 investigators. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0021","doi-asserted-by":"crossref","first-page":"TPS236","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS236","article-title":"Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design","volume":"42","author":"Azad","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0022","doi-asserted-by":"crossref","first-page":"TPS232","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS232","article-title":"EORTC GUCG 2238 De-escalate: a pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-na\u00efve prostate cancer in the era of new AR pathway inhibitors","volume":"42","author":"Guillaume","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0023","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.eururo.2020.06.033","article-title":"Association of SPOP mutations with outcomes in men with de novo metastatic castration-sensitive prostate cancer","volume":"78","author":"Swami","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clgc.2019.09.015","article-title":"Androgen receptor splice variant, AR-V7, as a biomarker of resistance to androgen axis-targeted therapies in advanced prostate cancer","volume":"18","author":"Zhang","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2025.10.012_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107669","article-title":"Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress","volume":"31","author":"Nyquist","year":"2020","journal-title":"Cell Rep"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925004107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:30:12Z","timestamp":1769257812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925004107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1078143925004107"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.10.012","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSA response to predict progression in metastatic hormone-sensitive prostate cancer (mHSPC) patients. When is the optimal time point?","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}